Chikungunya Virus Infection Clinical Trial
— CHIK13+Official title:
Consequences of a Maternal-fetal Chikungunya Virus Infection. Neurocognitive and Sensory Assessment Around the Age of 13.
Verified date | January 2024 |
Source | Centre Hospitalier Universitaire de la Réunion |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Chikungunya is an infectious disease caused by an alphavirus transmitted by the Aedes mosquitoes which has known a worldwide expansion since its re-emergence in 2004. Regarding to an unprecedented epidemic, Reunionese pediatricians described in 2005-2006 a vertical maternal-fetal transmission of this virus, at the time of childbirth. Since then, this mode of transmission has been widely confirmed, with an absolute risk estimated between 15.5% and 48.3%. The main consequences for the child are neuromotor, neurosensory or neurocognitive. They were studied around the age of 2 in 33 children in the CHIMERE cohort, as well as at the age of 5 in a small fraction of these children followed at the C.A.M.S.P (Center for Early Medico-Social Action). The results suggested an overall delay in psychomotor acquisitions secondary to neonatal infection, affecting the functions of the prefrontal region (in particular coordination and language). Performance was correlated with the severity of the clinical presentation (more severe in case of encephalitis or encephalopathy) while remaining suboptimal in children with uncomplicated infection. During neurodevelopmental monitoring, other disturbing traits complemented the spectrum of problems presented by these children, such as microcephaly, cerebral palsy, epilepsy, interaction disorder or attention deficit disorder. At around age 10, the investigators reassessed 21 of these children using the Childhood Cognitive Function and Learning (EDA) screening test. The investigators would now like to confirm and characterize their impairments using a battery of confirmatory tests around the age of 13.
Status | Completed |
Enrollment | 42 |
Est. completion date | October 12, 2021 |
Est. primary completion date | October 12, 2021 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 10 Years to 16 Years |
Eligibility | Inclusion Criteria: - Child born between March 2005 and July 2006 - Of which the mother identified in the CHIMERE cohort or the perinatal register of maternities - Exposed: child infected with the chikungunya virus at the time of childbirth - Not exposed: child not infected with the chikungunya virus at the time of childbirth, verifying the matching criteria specified in chapter 5.2 - Affiliated to a social insurance Exclusion Criteria: - Prematurity <33 weeks - Prenatal alcoholization authenticated by fetal alcohol syndrome - Intellectual disability or secondary epilepsy of origin other than CHIKV infection (caused by ACSOS or any other cause of brain damage of inflammatory, metabolic or infectious origin) |
Country | Name | City | State |
---|---|---|---|
Réunion | CHU de La Réunion | Saint-Pierre |
Lead Sponsor | Collaborator |
---|---|
Centre Hospitalier Universitaire de la Réunion |
Réunion,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Total intelligence quotient | Evaluation of total intelligence quotient with Wechsler Intelligence Scale for Children-5 | Month 3 (+/- 1 month) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02230163 -
Clinical Evaluation of Anti-CHIKV Hyperimmune Intravenous Immunoglobulins
|
Phase 1/Phase 2 | |
Completed |
NCT04546724 -
Pivotal Study to Evaluate Safety and Immunogenicity of a Live-Attenuated Chikungunya Virus Vaccine Candidate in Adults
|
Phase 3 | |
Terminated |
NCT04455919 -
Yoga for Chronic Chikungunya
|
N/A | |
Completed |
NCT03631719 -
Impact of Wolbachia Deployment on Arboviral Disease Incidence in Medellin and Bello, Colombia
|
||
Active, not recruiting |
NCT04441905 -
Phase 1 Study of SAR440894 vs Placebo
|
Phase 1 | |
Completed |
NCT02562482 -
Trial for Safety and Immunogenicity of a Chikungunya Vaccine, VRC-CHKVLP059-00-VP, in Healthy Adults
|
Phase 2 | |
Completed |
NCT03028441 -
Phase I Trial of Measles Vectored Chikungungya Vaccine
|
Phase 1 | |
Completed |
NCT03807843 -
Chikungunya Vaccine (V184) Study in Previously Exposed Adults (V184-006)
|
Phase 2 | |
Completed |
NCT04786444 -
Study to Demonstrate Consistency of Three Lots of a Live-attenuated Chikungunya Virus Vaccine Candidate in Healthy Adults
|
Phase 3 | |
Completed |
NCT02553369 -
Seroprevalence of Chikungunya at the End of the First Chikungunya Outbreak in the French Antilles Within a Sample of Patients Treated for a HIV Infection
|
N/A | |
Recruiting |
NCT06106581 -
A Phase 2 Clinical Study of VLA1553 in Healthy Children Aged 1 to 11 Years
|
Phase 2 | |
Recruiting |
NCT06007183 -
Long-term Follow-up Study to Evaluate Safety and Immunogenicity of PXVX0317 Single or Booster Vaccination
|
Phase 3 | |
Completed |
NCT03635086 -
Safety, Tolerability and Long-term Immunogenicity of Different Formulations of a Chikungunya Vaccine (V184-005)
|
Phase 2 | |
Completed |
NCT02861586 -
Phase II Study to Evaluate Safety and Immunogenicity of a Chikungunya Vaccine
|
Phase 2 | |
Active, not recruiting |
NCT04838444 -
Antibody Persistence And Long Term Safety Of A Chikungunya Virus Vaccine Candidate (VLA1553)
|
Phase 3 | |
Completed |
NCT03483961 -
Trial of a Chikungunya Vaccine, PXVX0317 CHIKV-VLP, in Healthy Adults
|
Phase 2 | |
Recruiting |
NCT06028841 -
A Clinical Phase 3 Study of VLA1553 in Adult Participants With Human Immunodeficiency Virus (HIV)
|
Phase 3 |